JoVE Logo
Autorzy
Skontaktuj Się z Nami

Zaloguj się

Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

W tym Artykule

  • Podsumowanie
  • Streszczenie
  • Wprowadzenie
  • Protokół
  • Wyniki
  • Dyskusje
  • Ujawnienia
  • Podziękowania
  • Materiały
  • Odniesienia
  • Przedruki i uprawnienia

Podsumowanie

This protocol describes the methodology for non-invasively tracking T cells genetically engineered to express chimeric antigen receptors in vivo with a clinically available platform.

Streszczenie

T cells genetically engineered to express chimeric antigen receptors (CAR) have shown unprecedented results in pivotal clinical trials for patients with B cell malignancies or multiple myeloma (MM). However, numerous obstacles limit the efficacy and prohibit the widespread use of CAR T cell therapies due to poor trafficking and infiltration into tumor sites as well as lack of persistence in vivo. Moreover, life-threatening toxicities, such as cytokine release syndrome or neurotoxicity, are major concerns. Efficient and sensitive imaging and tracking of CAR T cells enables the evaluation of T cell trafficking, expansion, and in vivo characterization and allows the development of strategies to overcome the current limitations of CAR T cell therapy. This paper describes the methodology for incorporating the sodium iodide symporter (NIS) in CAR T cells and for CAR T cell imaging using [18F]tetrafluoroborate-positron emission tomography ([18F]TFB-PET) in preclinical models. The methods described in this protocol can be applied to other CAR constructs and target genes in addition to the ones used for this study.

Wprowadzenie

Chimeric antigen receptor T (CAR T) cell therapy is a rapidly emerging and potentially curative approach in hematological malignancies1,2,3,4,5,6. Extraordinary clinical outcomes were reported after CD19-directed CAR T (CART19) or B cell maturation antigen (BCMA) CAR T cell therapy2. This led to the US Food and Drug Administration (FDA) approval of CART19 cells for aggressive B-cell lymphoma (axicabtagene ciloleucel (Axi-Cel)4, tisagenlecleucel (Tisa-Cel)3, and lisocabtagene maraleucel)7, acute lymphoblastic leukemia (Tisa-Cel)5,8, mantle cell lymphoma (brexucabtagene autoleuce)9, and follicular lymphoma (Axi-Cel)10. Most recently, the FDA approved BCMA-directed CAR T cell therapy in patients with multiple myeloma (MM) (idecabtagene vicleucel)11. Moreover, CAR T cell therapy for chronic lymphocytic leukemia (CLL) is in late-stage clinical development and is expected to receive FDA approval within the next three years1.

Despite the unprecedented results of CAR T cell therapy, its widespread use is limited by 1) insufficient in vivo CAR T cell expansion or poor trafficking to tumor sites, which leads to lower rates of durable response12,13 and 2) the development of life-threatening adverse events, including cytokine release syndrome (CRS)14,15. The hallmarks of CRS include not only immune activation resulting in elevated levels of inflammatory cytokines/chemokines but also massive T cell proliferation after CAR T cell infusion15,16. Thus, the development of a validated, clinical-grade strategy to image CAR T cells in vivo would allow 1) CAR T cell tracking in real time in vivo to monitor their trafficking to tumor sites and uncover potential mechanisms of resistance, and 2) monitoring of CAR T cell expansion and potentially predicting their toxicities such as the development of CRS.

Clinical features of mild CRS are high fever, fatigue, headache, rash, diarrhea, arthralgia, myalgia, and malaise. In more severe CRS, patients may develop tachycardia/hypotension, capillary leak, cardiac dysfunction, renal/hepatic failure, and disseminated intravascular coagulation17,18. In general, the degree of elevation of cytokines, including interferon-gamma, granulocyte-macrophage colony-stimulating factor, interleukin (IL)-10, and IL-6, has been shown to correlate with the severity of clinical symptoms17,19. However, the extensive application of "real-time" serum cytokine monitoring to predict CRS is difficult due to the high cost and limited availability. To exploit the beneficial characteristics of CAR T cell therapy, non-invasive imaging of adoptive T cells can be potentially utilized to predict the efficacy, toxicities, and relapse after CAR T cell infusion.

Several researchers have developed strategies to use radionuclide-based imaging with positron emission tomography (PET) or single-photon emission computed tomography (SPECT), which provides high resolution and high sensitivity20,21,22,23,24,25,26,27,28,29,30 for the in vivo visualization and monitoring of CAR T cell trafficking. Among those radionuclide-based imaging strategies, the sodium iodide symporter (NIS) has been developed as a sensitive modality to image cells and viruses using PET scans31,32. NIS+CAR T cell imaging with [18F]TFB-PET is a sensitive, efficient, and convenient technology to assess and diagnose CAR T cell expansion, trafficking, and toxicity30. This protocol describes 1) the development of NIS+CAR T cells through dual transduction with high efficacy and 2) a methodology for imaging NIS+CAR T cells with [18F]TFB-PET scan. BCMA-CAR T cells for MM are used as a proof-of-concept model to describe NIS as a reporter for CAR T cell imaging. However, these methodologies can be applied to any other CAR T cell therapy.

Access restricted. Please log in or start a trial to view this content.

Protokół

The protocol follows the guidelines of Mayo Clinic's Institutional Review Board, Institutional Biosafety Committee, and Mayo Clinic's Institutional Animal Care and Use Committee.

1. NIS+ BCMA-CAR T cell production

NOTE: This protocol follows the guidelines of the Mayo Clinic's Institutional Review Board (IRB 17-008762) and Institutional Biosafety Committee (IBC Bios00000006.04).

  1. Production of BCMA-CAR, NIS, and luciferase-green fluorescent protein (GFP)-encoding lentiviruses.
    NOTE: A second-generation BCMA-CAR construct was synthesized de novo (see the Table of Materials) and cloned into a third-generation lentiviral vector under the control of an elongation factor-1 alpha (EF-1α) promotor. The BCMA-CAR construct (C11D5.3-41BBz) included 4-1BB costimulation and a single-chain variable fragment (scFv) derived from an anti-human BCMA antibody clone C11D5.333,34. The NIS is under the control of the EF-1α promotor and binds to the puromycin resistance gene via self-cleaving peptides (P2A). The lentiviral vector encoding luciferase-GFP (see the Table of Materials) is used to transduce tumor cells, which then express GFP and luciferase.
    1. Prepare lentiviral vector plasmids: pLV-EF1α-BCMA-CAR (15 µg), pBMN-CMV-GFP-Luc2-Puro (15 µg), and pLV-EF1α-NIS-P2A-Puro (15 µg).
      NOTE: pBMN-CMV-GFP-Luc2-Puro and pLV-EF1α-NIS-P2A-Puro contain the puromycin resistance gene. Therefore, NIS- or luciferase-GFP-transduced cells can be selected with 1 µg/mL or 2 µg/mL of puromycin dihydrochloride, as described previously14,35.
    2. Seed 20 × 106 of 293T cells in a T175 flask and incubate for 24 h at 37 °C with 5% CO2. Confirm that 293T cells are evenly distributed on the flask at 70-90% confluence by direct visualization under the microscope.
    3. Prepare a master mix of 15 µg of the expression vector (e.g., CAR, NIS, or luciferase-GFP linear DNA), 7 µg of the envelope vector (VSV-G), and 18 µg of the packaging vector (gag, pol, rev, and tat). Dilute the DNA master mix in 4.5 mL of the transfection medium, and then add 111 µL of the pre-complexing reagent (Mixture A).
    4. Prepare a new tube, and dilute 129 µL of the liposomal transfection reagent in 4.5 mL of the transfection medium (Mixture B).
    5. Combine Mixtures A and B and flick the tube to mix the contents. Incubate for 30 min at room temperature (RT).
    6. After the incubation, simply aspirate the cell supernatant without detaching the cells and add 16 mL of a growth medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin-glutamine. Then, add the mixture of Mixtures A and B on 293T cells dropwise. Finally, incubate the transfected cells at 37 °C, 5% CO2 for 24 h.
    7. On days 1 and 2 post-transfection, harvest the supernatant of 293T, spin down at 900 × g for 10 min, and filter through a 0.45 µm nylon filter. Concentrate the filtrate at 24 and 48 h by ultracentrifugation at 112,700 × g for 2 h, and freeze at -80 °C.
  2. Ex-vivo T cell isolation (Figure 1)
    NOTE: Perform all cell culture work in a laminar flow cabinet using aseptic technique and personal protective equipment. Peripheral blood mononuclear cells (PBMCs) are harvested from healthy volunteer donor blood collected during apheresis36. Pathogen screening was performed on human cells used in this study.
    1. Use the standard density gradient technique to isolate PBMCs.
      1. Gently add 15 mL of density gradient medium (density of 1.077 g/mL) (containing alpha-D-glucopyranoside, beta-D-fructofuranosyl homopolymer, and, 3-(acetylamino)-5-(acetylmethylamino)-2,4,6-triodobenzoic acid monosodium salt) to a 50 mL density gradient separation tube without creating air bubbles (see the Table of Materials).
      2. To avoid cell trapping, dilute the blood sample with phosphate-buffered saline (PBS, 0.2 g/L of potassium chloride, 0.2 g/L of potassium phosphate monobasic, 8 g/L of sodium chloride, and 1.15 g/L of sodium phosphate dibasic) containing 2% FBS at a 1:1 volume ratio. Gently transfer the diluted blood on top of the density gradient medium without breaking the interface between the two. Spin down at 1,200 × g for 10 min at RT.
        NOTE: A 50 mL density gradient separation tube can be used for the isolation of 4-17 mL of a blood sample. The 50 mL density gradient separation tube (see the Table of Materials) used in this protocol does not require the "brake off" during centrifugation. However, when standard 50 mL tubes are used, the brake needs to be off and requires 30 min centrifugation.
      3. Transfer the supernatant into a new 50 mL conical tube, wash with PBS + 2% FBS by filling up to 50 mL, and then spin down at 300 × g for 8 min at RT.
      4. Aspirate the supernatant, and resuspend the pelleted cells in 50 mL of PBS + 2% FBS. Count the number of cells, and then spin down at 300 × g for 8 min at RT. Repeat the previous step for a total of 2 washes.
    2. Aspirate the supernatant, and resuspend the pelleted cells to a concentration of 50 × 106 cells/mL with PBS + 2% FBS.
    3. Perform T cell isolation from PBMCs using a negative selection magnetic bead kit.
      NOTE: An ideal negative selection kit includes magnetic beads attached to antibodies against antigens expressed on cells other than T cells. A commonly used kit contains antibodies conjugated to magnetic beads against CD15, CD14, CD34, CD36, CD56, CD123, CD235a, CD19, and CD16 (see Table of Materials).
      1. Transfer PBMCs to a 14 mL polystyrene round-bottom tube. Then, place the PBMCs and the negative selection antibody cocktail in a fully automated cell separator, and perform T cell isolation according to the manufacturer's protocol.
  3. T cell stimulation and T cell expansion (Figure 1)
    1. To culture the isolated T cells, prepare T cell expansion medium (TCM) made with serum-free hematopoietic cell medium supplemented with 10% human serum albumin and 1% penicillin-streptomycin-glutamine14. After T cell isolation, count the cells and culture at a concentration of 2 × 106 cells/mL with TCM.
    2. Wash anti-CD3/CD28 beads three times with TCM before culturing with T cells.
      1. Mix the vial containing the beads by swirling. Then, pipette the required volume of beads (3:1 beads:cell) (e.g., when stimulating 1.0 × 106 cells of T cells, use 3.0 × 106 of anti-CD3/CD28 beads) into a sterile microcentrifuge tube (1.5 mL) and resuspend in 1 mL of TCM.
    3. Place the microcentrifuge tube with the beads on a magnet for 1 min, and aspirate the supernatant. Remove the tube from the magnet, and resuspend the washed beads in 1 mL of TCM. Repeat the previous two steps for a total of 3 washes.
    4. Resuspend the beads in 1 mL of TCM and transfer them to the T cells. Then, dilute the T cells to a final concentration of 1.0 × 106 cells/mL with TCM. Transfer the T-cell/bead suspension to a tissue-culture-treated 6-well plate and place it in the incubator (37 °C, 5% CO2).
  4. Titration of lentiviruses (Figure 2)
    1. Prepare T cells for titration assay. Ensure that approximately 1.0 x 106 cells are available to titrate one type of virus.
    2. Stimulate T cells as described in section 1.3.2.
    3. Plate 1.0 × 105 cells of stimulated T cells in a 96-well plate (titer plate) and incubate at 37 °C, 5% CO2 for 24 h (Figure 2A). Isolate and stimulate the T cells as described in section 1.2.
    4. Prepare a dilution plate (96-well plate) by adding 100 µL of TCM into the wells of the designated columns and the untransduced control wells (Figure 2B).
    5. Thaw one vial of lentiviral particles on ice and gently pipette up and down to mix well. Transfer 50 µL of the virus supernatant into the wells of Column 6 of the 96-well plate (dilution 3) (Figure 2B). Pipette up and down to mix well.
    6. Perform serial dilutions (2-fold serial dilution): transfer 50 µL from well A6 to well B6 and then 50 µL from well B6 to well C6; repeat until G6. Then, add 50 µL of the diluted virus to the titer plate (Figure 2B).
    7. Incubate the titer plate at 37 °C, 5% CO2 for 48 h, and determine the percentages of CAR-, NIS-, or GFP-positive cells by flow cytometry (Figure 2C).
      1. Wash the wells by spinning down the titer plate two times at 650 × g at 4 °C for 3 min.
      2. Stain the transduced T cells as described in steps 1.5.3 to 1.5.9.
      3. Determine the titers based on the percentages of CAR-, NIS-, or GFP-positive cells by using formula (1):
        Titers = Percentage of BCMA-CAR+ or NIS+ T cells × T cell count at transduction × the specific dilution / volume (1)
  5. Transduction of lentiviruses and NIS+BCMA-CAR T cell expansion
    1. Twenty-four to 48 h after T cell stimulation, perform lentiviral transduction on stimulated T cells (T cells should form clusters).
      1. Thaw the frozen lentiviruses encoding CAR or NIS at 4 °C.
      2. Mix the stimulated T cells well to break up the clusters, and simply add freshly thawed virus at a multiplicity of infection (MOI) of 5.0 (when transducing 1.0 × 106 T cells, use 5.0 × 106 of lentivirons). Incubate the transduced cells at 37 °C, 5% CO2.
      3. On days 3, 4, and 5, count the transduced T cells using a hematocytometer37 or a fully automated cell counter38 and adjust the cell concentration to 1.0 × 106 cells/mL by adding fresh, pre-warmed TCM. For NIS-transduced T cells carrying the puromycin resistance gene, treat the cells with 1 µg/mL of puromycin dihydrochloride on days 3, 4, and 5.
    2. On day 6, remove the anti-CD3/CD28 beads from the transduced T cells (from step 1.3.4) by mixing well to break up the T cell clusters and placing them in a magnet for 1 min. Then, simply place the collected transduced T cells back in culture at a concentration of 1.0 × 106 cells/mL. After removing the beads from the T cells, assess the expression of CAR and NIS by flow cytometry.
      NOTE: As the single-chain variable fragment of the BCMA-CAR is derived from mouse, it can be stained with goat anti-mouse IgG (H+L) conjugated with Alexa Fluor 647. NIS can be detected using anti-human ETNL [synthetic peptide corresponding to aa625-643 (SWTPCVGHDGGRDQQETNL)]. This antibody recognizes the cytosolic C-terminus of NIS. Therefore, T cells must be permeabilized before incubation with an anti-human NIS antibody.
    3. Perform surface staining of BCMA-CAR using goat anti-mouse IgG (H+L).
      1. Take an aliquot of the culture (e.g., 50,000 T cells) and wash with flow buffer (PBS, 1% FBS, and 1% sodium azide). Next, resuspend the cells with 50 µL of flow buffer, and stain the cells with 1 µL of goat anti-mouse antibody for detecting CAR expression and 0.3 µL of live-dead aqua for excluding dead cells.
      2. Incubate for 15 min in the dark at RT, wash the cells by adding 150 µL of flow buffer, and centrifuge the cells at 650 × g for 3 min at 4 °C.
    4. After surface CAR staining, fix and permeabilize the cells by adding 100 µL of fixation medium (PBS with 4.21% formaldehyde) and incubate for 20 min at 4 °C. Wash the cells twice with 100 µL of a buffer that contains a cell-permeabilizing agent such as saponin (650 × g for 3 min at 4 °C).
    5. Resuspend the fixed/permeabilized cells in 50 µL of a permeabilizing buffer. Then, add 0.3 ng of anti-human ETNL NIS antibody in 50 µL of flow buffer and incubate for 1 h at 4 °C.
    6. Add 150 µL of flow buffer, and centrifuge the cells at 650 × g for 3 min at 4 °C. Incubate the cells with 2.5 µL of anti-rabbit secondary antibody in 50 µL of flow buffer for 30 min at 4 °C, wash the cells by adding 150 µL of flow buffer, and centrifuge at 650 × g for 3 min at 4 °C.
    7. Finally, resuspend in 200 µL of flow buffer and perform flow cytometry to determine the transduction efficiency (Figure 3A,B).
    8. On day 8, count and spin down the T cells at 300 × g for 8 min at 4 °C. Resuspend the T cells with freezing medium (90% FBS + 10% dimethylsulfoxide [DMSO]) at a concentration of 10 × 106/mL, then transfer 1 mL each to labeled cryovials.
    9. Place the vials in a -80 °C freezer for 48 h. After 48 h (and by day 10), transfer the T cells to liquid nitrogen.
      NOTE: See Figure 1 for the overview of NIS+ CAR T cell production. Figure 3D represents examples of ex vivo T cell expansion from three different donors.

2. NIS+ BCMA-CAR T cell imaging with [ 18F]TFB-PET scan

NOTE: This protocol follows the guidelines of Mayo Clinic's Institutional Animal Care and Use Committee (IACUC A00001767-16), IRB, and IBC (Bios00000006.04). OPM-2 is a BCMA+ MM cell line, which is often used as a target cell line for BCMA-CAR T cells39,40.

  1. Establish luciferase+ BCMA+ OPM-2 cells.
    1. Seed 500,000 OPM-2 cells in a tissue culture-treated 24-well plate. Thaw lentivirus encoding luciferase-GFP at 4 °C.
    2. Add the freshly thawed virus at an MOI of 3.0 to OPM-2 cells and mix well by pipetting. Place the plate in the incubator (37 °C, 5% CO2).
    3. Forty-eight hours after the transduction, add 2 µg/mL of puromycin to select the transduced cells. Four days after the transduction, assess the GFP-positive cells (luciferase-positive) by flow cytometry (Figure 3E).
  2. Establish BCMA+ OPM-2 xenograft mouse models (Figure 4).
    1. Count luciferase+ OPM-2 cells and spin them down twice to remove all cell culture medium. Resuspend the OPM-2 cells at a concentration of 10 × 106 cells/mL with PBS.
    2. On day -21, inject 100 µL (1.0 × 106 cells) of luciferase+ OPM-2 cells into the tails of 8-to-12-week-old immunocompromised NOD-scid IL2rγnull (NSG) mice (Figure 4).
    3. On day 20 after the OPM-2 cell injection (day -1 of CAR T cell injection), check the tumor burden via bioluminescence imaging (BLI) (Figure 4).
      NOTE: OPM-2 cells form a slow-growing tumor, which usually takes 2-3 weeks to engraft.
    4. Administer 10 µL/g of D-luciferin to OPM-2 xenograft mice via intraperitoneal (IP) injection. After 10 min, perform BLI on the mice under 2% isoflurane gas (Figure 5A). After confirming tumor engraftment, randomize the mice according to the tumor burden.
    5. On day -1 of the CAR T cell injection, thaw NIS+BCMA-CAR T cells, and remove the freezing medium by centrifugation (300 × g, 8 min, 4 °C). Then, the resuspend cells with TCM at 2.0 × 106 cells/mL and incubate overnight (37 °C, 5% CO2).
    6. On day 0, count and centrifuge the NIS+BCMA-CAR T cells (300 × g, 8 min, 4 °C). Resuspend the NIS+BCMA-CAR T cells at 50 × 106 cells/mL with PBS.
    7. Administer 100 µL (5.0 × 106 cells) of NIS+BCMA-CAR T cells via tail vein injection to the OPM-2 xenograft mice. On days 7 and 15, image the mice using a PET scan.
  3. NIS+BCMA-CAR T cell in vivo imaging using BCMA+OPM-2 xenograft mouse model.
    1. Weigh the mice before the imaging, and remove any metal ear tags to eliminate metal-related artifacts.
    2. Prepare [18F]TFB as previously described41.
      NOTE: [18F]TFB must be produced the day of its use. Radiochemical purity should be >99% and molar activity >5 GBq/mmol.
    3. Inject 9.25 MBq [18F]TFB intravenously via tail vein injection. Allow an uptake period of ~40 min for the radiotracer to be distributed in the body and clear the blood.
    4. Anesthetize the mouse using isoflurane inhalation (2%).
      NOTE: Isoflurane is the preferred inhaled anesthetic as it has rapid and reliable onset and recovery.
    5. Prior to anesthetizing the mouse, clean all surfaces of the anesthesia machine with disinfectant cleaners.
    6. Place the mouse inside the induction chamber. Turn the vaporizer dial to 2% and wait for the mouse to become recumbent and non-responsive within 1-2 min.
    7. Monitor the mouse to avoid insufficient anesthesia or excessive depression of respiratory functions. In brief, pinch toe to confirm the insufficient anesthesia.
      NOTE: The normal respiratory rate is up to 180/min, and the acceptable drop rate is 50%.
    8. Apply ophthalmic ointment to avoid corneal drying and trauma.
    9. Acquire PET/CT images 45 min post-injection with the anesthetized mouse in a micro PET/CT imaging workstation (see the Table of Materials). Next, acquire static PET images for 15 min followed by CT image acquisition for 5 min with 360° rotation and 180 projections at 500 µA, 80 keV, and 200 ms exposure.
  4. Analyzing acquired imaging data
    1. Analyze the images using PET image processing software (Figure 5B and Supplemental Video S1).
    2. Define the volume of interest (VOI).
    3. Calculate the standardized uptake value (SUV) using formula (2).
      SUV in VOI = Concentration of activity in VOI (MBq/mL) × body weight (g) / administered dose (MBq)  (2)
  5. Confirmation of NIS+BCMA-CAR T cell trafficking to the tumor sites with the flow cytometry
    1. After [18F]TFB-PET imaging, place the mouse back into the cage. Following cessation of anesthesia, monitor the animals until they are capable of purposeful movement and ensure that they have access to food and water.
    2. Monitor the mice until the decay of the injected [18F]TFB. Once the radioisotope is not detectable, euthanize the mice with CO2.
    3. To euthanize, place the mice into the cage (no more than 5 mice per cage).
    4. Expose the mice to CO2 until complete cessation of breathing in approximately 5-10 min.
      NOTE: This euthanasia method must be consistent with the AVMA Guidelines for the Euthanasia of Animals (2020 Edition).
    5. To ensure the death of the mice, perform cervical dislocation by grasping the back of the head and the base of the tail of the animal, then pulling hands apart/away from each other.
    6. Harvest the bone marrow to confirm that the NIS+BCMA-CAR T cells efficiently traffic to the tumor site.
    7. Transfer the harvested femurs and tibia to a 6-well plate containing 5 mL of cell culture medium. Remove the muscles and tendons from the femurs and tibia, and simply cut both ends (above the joints) of the femurs and tibia.
    8. Fill an insulin syringe with the cell culture medium, and flush bone marrow onto the 6-well plate. For femurs, use 22 G needles and 5 mL syringes because the femur diameter is larger than that of the tibia.
    9. Use the flat end of the plunger to grind the bone marrow. Place a 70 µm cell strainer on a sterile 50 mL conical tube, and filter the ground bone marrow. Then, fill up the tube with the flow buffer, and centrifuge the tube at 300 × g for 8 min at 4 °C.
    10. Aspirate the supernatant, and resuspend the bone marrow with 5 mL of flow buffer. Transfer 200 µL of bone marrow to a 96-well plate. Centrifuge the plate at 300 × g for 3 min at 4 °C. Decant the supernatant, and resuspend the cells with 50 µL of flow buffer.
    11. Stain the bone marrow with flow antibodies against 0.25 µg of mouse CD45, 0.03 µg of human CD45, 0.06 µg of human CD3, 0.24 µg of human BCMA, and 0.3 µL of live/dead aqua. Incubate the plate for 15 min at RT in the dark.
    12. Centrifuge the plate at 300 × g for 3 min at 4 °C. Then, add 200 µL of flow buffer, and run on the flow cytometer (Figure 5C).

Access restricted. Please log in or start a trial to view this content.

Wyniki

Figure 1 represents the steps of generating NIS+BCMA-CAR T cells. On day 0, isolate PBMCs and then isolate T cells by negative selection. Then, stimulate T cells with anti-CD3/CD28 beads. On day 1, transduce T cells with both NIS and BCMA-CAR lentiviruses. On days 3, 4, and 5, count T cells and feed with media to adjust the concentration to be 1.0 × 106/mL. For NIS-transduced T cells, add 1 μg/mL of puromycin to select NIS+ cells. On day 6, remove t...

Access restricted. Please log in or start a trial to view this content.

Dyskusje

This paper describes a methodology for incorporating NIS into CAR T cells and imaging infused CAR T cells in vivo through [18F]TFB-PET. As proof of concept, NIS+BCMA-CAR T cells were generated via dual transduction. We have recently reported that incorporating NIS into CAR T cells does not impair CAR T cell functions and efficacy in vivo and allows CAR T cell trafficking and expansion30. As CAR T cell therapies continue to expand beyond the current B cell ma...

Access restricted. Please log in or start a trial to view this content.

Ujawnienia

SSK is an inventor on patents in CAR immunotherapy licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis) and Mettaforge (through Mayo Clinic). RS, MJC, and SSK are inventors on patents in the field of CAR immunotherapy that are licensed to Humanigen. SSK receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, Leahlabs, and Lentigen. Figures were created with BioRender.com.

Podziękowania

This work was partly supported through the Mayo Clinic K2R pipeline (SSK), the Mayo Clinic Center for Individualized Medicine (SSK), and the Predolin Foundation (RS). Figures 1, 2, and 4 were created with BioRender.com.

Access restricted. Please log in or start a trial to view this content.

Materiały

NameCompanyCatalog NumberComments
22 Gauge needleCovidien8881250206
28 gauge insulin syringeBD329461
96 well plateCorning3595
Anti-human (ETNL) NISImanisREA009ETNL antibody binds the cytosolic C-terminus of NIS
Anti-human BCMA, clone 19F2, PE-Cy7BioLegend357507Flow antibody
Anti-human CD45, clone HI30, BV421BioLegend304032Flow antibody
Anti-mouse CD45, clone 30-F11, APC-Cy7BioLegend103116Flow antibody
Anti-rabbit IgGR&DF0110Secondary antibody for NIS staining
BCMA-CAR construct, second generationIDT, Coralville, IA
BD Cytofix/Cytoperm Fixation/Permeabilization Solution KitBD554714
CD3 Monoclonal Antibody (OKT3), PE, eBioscienceInvitrogen12-0037-42
CTS (Cell Therapy Systems) Dynabeads CD3/CD28Gibco40203D
CytoFLEX System  B5-R3-V5Beckman CoulterC04652flow cytometer
Dimethyl sulfoxideMillipore SigmaD2650-100ML
Disposable Syringes with Luer-Lok TipsBD309646
D-Luciferin, Potassium SaltGold BiotechnologyLUCK-1G
D-PBS (Dulbecco's phosphate-buffered saline)Gibco14190-144
Dulbecco's Phosphate-Buffered SalineGibco14190-144
Dynabeads MPC-S (Magnetic Particle Concentrator)Applied BiosystemsA13346
Easy 50 EasySep MagnetSTEMCELL Technologies18002
EasySep Human T Cell Isolation KitSTEMCELL Technologies17951negative selection magnetic beads; 17951RF includes tips and buffer
Fetal bovine serumMillipore SigmaF8067
Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647InvitrogenA-21235
Inveon Multiple Modality PET/CT scannerSiemens Medical Solutions USA, Inc.10506989 VFT 000 03
Isoflurane liquidPiramal Critical Care66794-017-10
IVIS Lumina S5 Imaging SystemPerkinElmerCLS148588
IVIS® Spectrum In Vivo Imaging SystemPerkinElmer 124262
Lipofectamine 3000 Transfection ReagentInvitrogenL3000075
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit, for 405 nm excitationInvitrogenL34966
LymphoprepSTEMCELL Technologies07851
Nalgene Rapid-Flow 500 mL Vacuum Filter, 0.22 uM, sterileThermo Scientific450-0020
Nalgene Rapid-Flow 500 mL Vacuum Filter, 0.45 uM, sterileThermo Scientific450-0045
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJJackson laboratory05557
OPM-2DSMZCRL-3273multiple myeloma cell line
pBMN(CMV-copGFP-Luc2-Puro)Addgene80389lentiviral vector encoding luciferase-GFP
Penicillin-Streptomycin-Glutamine (100x), LiquidGibco10378-016
PMOD softwarePMODPBAS and P3D
Pooled Human AB Serum Plasma DerivedInnovative ResearchIPLA-SERAB-H-100ML
Puromycin DihydrochlorideMP Biomedicals, Inc.0210055210
RoboSep-SSTEMCELL Technologies21000Fully Automated Cell Separator
RPMI (Roswell Park Memorial Institute (RPMI) 1640 Medium)Gibco21870-076
SepMate-50 (IVD)STEMCELL Technologies85450density gradient separation tubes
Sodium Azide, 5% (w/v)Ricca Chemical7144.8-16
T175 flaskCorning353112
Terrell (isoflurane, USP)Piramal Critical Care Inc66794-019-10
Webcol Alcohol PrepCovidien6818
X-VIVO 15 Serum-free Hematopoietic Cell MediumLonza04-418Q

Odniesienia

  1. Porter, D. L., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine. 7 (303), (2015).
  2. Raje, N., et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine. 380 (18), 1726-1737 (2019).
  3. Schuster, S. J., et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine. 380 (1), 45-56 (2019).
  4. Neelapu, S. S., et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine. 377 (26), 2531-2544 (2017).
  5. Maude, S. L., et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine. 378 (5), 439-448 (2018).
  6. Anagnostou, T., Riaz, I. B., Hashmi, S. K., Murad, M. H., Kenderian, S. S. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematology. 7 (11), 816-826 (2020).
  7. Abramson, J. S., et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 396 (10254), 839-852 (2020).
  8. Shah, B. D., et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 398 (10299), 491-502 (2021).
  9. Wang, M., et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine. 382 (14), 1331-1342 (2020).
  10. Jacobson, C. A., et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncology. 23 (1), 91-103 (2022).
  11. Munshi, N. C., et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine. 384 (8), 705-716 (2021).
  12. Sakemura, R., Cox, M. J., Hefazi, M., Siegler, E. L., Kenderian, S. S. Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leukemia & Lymphoma. , 1-18 (2021).
  13. Cox, M. J., et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Molecular Therapy. 29 (4), 1529-1540 (2021).
  14. Sterner, R. M., et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 133 (7), 697-709 (2019).
  15. Siegler, E. L., Kenderian, S. S. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Frontiers in Immunology. 11, 1973(2020).
  16. Khadka, R. H., Sakemura, R., Kenderian, S. S., Johnson, A. J. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 11 (10), 851-857 (2019).
  17. Hay, K. A., et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 130 (21), 2295-2306 (2017).
  18. Lee, D. W., et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation. 25 (4), 625-638 (2019).
  19. Sterner, R. M., Kenderian, S. S. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Current Opinion in Hematology. 27 (1), 41-48 (2020).
  20. Krekorian, M., et al. Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics. 9 (25), 7924-7947 (2019).
  21. Wei, W., Jiang, D., Ehlerding, E. B., Luo, Q., Cai, W. Noninvasive PET imaging of T cells. Trends in Cancer. 4 (5), 359-373 (2018).
  22. Volpe, A., et al. Spatiotemporal PET imaging reveals differences in CAR-T tumor retention in triple-negative breast cancer models. Molecular Therapy. 28 (10), 2271-2285 (2020).
  23. Minn, I., et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Science Advances. 5 (7), (2019).
  24. Keu, K. V., et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science Translational Medicine. 9 (373), (2017).
  25. Moroz, M. A., et al. Comparative analysis of T cell imaging with human nuclear reporter genes. Journal of Nuclear Medicine. 56 (7), 1055-1060 (2015).
  26. Sellmyer, M. A., et al. Imaging CAR T cell trafficking with eDHFR as a PET reporter gene. Molecular Therapy. 28 (1), 42-51 (2019).
  27. Weist, M. R., et al. PET of adoptively transferred chimeric antigen receptor T cells with (89)Zr-oxine. Journal of Nuclear Medicine. 59 (89), 1531-1537 (2018).
  28. Vedvyas, Y., et al. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight. 1 (19), 90064(2016).
  29. Sakemura, R., Can, I., Siegler, E. L., Kenderian, S. S. In vivo CART cell imaging: Paving the way for success in CART cell therapy. Molecular Therapy Oncolytics. 20, 625-633 (2021).
  30. Sakemura, R., et al. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. Cancer Immunology Research. 9 (9), 1035-1046 (2021).
  31. Penheiter, A. R., Russell, S. J., Carlson, S. K. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Current Gene Therapy. 12 (1), 33-47 (2012).
  32. Msaouel, P., et al. Clinical trials with oncolytic measles virus: current status and future prospects. Current Cancer Drug Targets. 18 (2), 177-187 (2018).
  33. Kalled, S. L., Hsu, Y. -M. Anti-BCMA antibodies. , WO/2010/10949 (2010).
  34. Carpenter, R. O., et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research. 19 (8), 2048-2060 (2013).
  35. Sterner, R. M., Cox, M. J., Sakemura, R., Kenderian, S. S. Using CRISPR/Cas9 to knock out GM-CSF in CAR-T cells. Journal of Visualized Experiments. (149), e59629(2019).
  36. Dietz, A. B., et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion. 46 (12), 2083-2089 (2006).
  37. Absher, M. Tissue Culture: Methods and Applications. Kruse, P. F., Patterson, M. K. , Academic Press Inc. 395-397 (1973).
  38. Janakiraman, V., Forrest, W. F., Chow, B., Seshagiri, S. A rapid method for estimation of baculovirus titer based on viable cell size. Journal of Virological Methods. 132 (1-2), (2006).
  39. Smith, E. L., et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine. 11 (485), (2019).
  40. Sakemura, R., et al. Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma. Blood. , (2022).
  41. Jiang, H., et al. Synthesis of 18F-tetrafluoroborate via radiofluorination of boron trifluoride and evaluation in a murine C6-glioma tumor model. Journal of Nuclear Medicine. 57 (9), 1454-1459 (2016).
  42. Dispenzieri, A., et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia. 31 (12), 2791-2798 (2017).
  43. Ravera, S., Reyna-Neyra, A., Ferrandino, G., Amzel, L. M., Carrasco, N. The sodium/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annual Review of Physiology. 79, 261-289 (2017).
  44. Varettoni, M., et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology. 21 (2), 325-330 (2010).
  45. Bladé, J., et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. Journal of Clinical Oncology. 29 (28), 3805-3812 (2011).
  46. Brunton, B., et al. New transgenic NIS reporter rats for longitudinal tracking of fibrogenesis by high-resolution imaging. Scientific Reports. 8 (1), 14209(2018).
  47. Dohán, O., et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocrine Reviews. 24 (1), 48-77 (2003).
  48. Jiang, H., DeGrado, T. R. 18F]Tetrafluoroborate ([18F]TFB) and its analogs for PET imaging of the sodium/iodide symporter. Theranostics. 8 (14), 3918-3931 (2018).
  49. Ahn, B. -C. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics. 2 (4), 392-402 (2012).
  50. Gust, J., et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery. 7 (12), 1404-1419 (2017).
  51. Gofshteyn, J. S., et al. Neurotoxicity after CTL019 in a pediatric and young adult cohort. Annals of Neurology. 84 (4), 537-546 (2018).
  52. Shalabi, H., et al. Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. Journal of Immunotherapy. 41 (7), 350-358 (2018).
  53. Ruff, M. W., Siegler, E. L., Kenderian, S. S. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. Neurologic Clinics. 38 (4), 953-963 (2020).
  54. Santomasso, B. D., et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery. 8 (8), 958-971 (2018).

Access restricted. Please log in or start a trial to view this content.

Przedruki i uprawnienia

Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE

Zapytaj o uprawnienia

Przeglądaj więcej artyków

Chimeric Antigen ReceptorCAR T cellsImaging PlatformPET ScanSodium iodide SymporterTLP PET ImagingEfficacy PredictionToxicity PredictionPeripheral Blood Mononuclear CellsDensity Gradient TechniqueT cell TraffickingNegative Selection Magnetic Bead KitT cell Expansion Medium

This article has been published

Video Coming Soon

JoVE Logo

Prywatność

Warunki Korzystania

Zasady

Skontaktuj Się z Nami

Poleć Bibliotece

BIULETYNY JoVE

Badania

Edukacja

Autorzy

Bibliotekarze

O JoVE

Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone